Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The coming of age of molecular tumor profiling.

Antonoff MB, D'Cunha J.

Semin Thorac Cardiovasc Surg. 2011 Spring;23(1):8-9. doi: 10.1053/j.semtcvs.2011.03.005.

PMID:
21807290
2.

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS.

J Clin Oncol. 2010 Oct 10;28(29):4417-24. doi: 10.1200/JCO.2009.26.4325. Epub 2010 Sep 7. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126. J Clin Oncol. 2014 Feb 1;32(4):365.

3.

Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, Wada H.

Eur J Cardiothorac Surg. 1998 Sep;14(3):256-62; discussion 263-4.

PMID:
9761434
4.

The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer.

Shapiro M.

Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS42-5. doi: 10.3949/ccjm.79.s2.09. Review.

5.

Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.

Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, André F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E.

J Clin Oncol. 2007 Jul 1;25(19):2735-40.

PMID:
17602078
6.

The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H.

Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):73-7. Review.

PMID:
17505412
7.

Predicting response to chemotherapy with early-stage lung cancer.

Rosell R, Taron M, Massuti B, Mederos N, Magri I, Santarpia M, Sanchez JM.

Cancer J. 2011 Jan-Feb;17(1):49-56. doi: 10.1097/PPO.0b013e3182091fa3. Review.

PMID:
21263267
8.

Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.

Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Régnard JF, Lim E, Tan P, Miller LD.

Cancer Res. 2009 Feb 1;69(3):1055-62. doi: 10.1158/0008-5472.CAN-08-1116. Epub 2009 Jan 27.

9.

[An approach to individualised therapy of non-small cell lung carcinoma (NSCLC)--relevance of molecular predictive and prognostic factors].

Zirlik S, Lampert S, Hahn EG, Wiest GH, Brückl WM.

Pneumologie. 2007 Nov;61(11):731-8. Epub 2007 Oct 18. Review. German.

PMID:
17948172
10.

Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer.

Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL.

Mol Cancer. 2010 Jun 17;9:152. doi: 10.1186/1476-4598-9-152.

12.

[Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].

Nakajima E, Katou H.

Kyobu Geka. 2008 Jan;61(1):4-8. Review. Japanese.

PMID:
18186265
13.

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.

Breen D, Barlési F.

Eur J Cardiothorac Surg. 2008 May;33(5):805-11. doi: 10.1016/j.ejcts.2008.01.067. Epub 2008 Mar 14. Review.

PMID:
18342529
14.

Adjuvant chemotherapy in early-stage non-small cell lung cancer.

Dômont J, Soria JC, Le Chevalier T.

Semin Oncol. 2005 Jun;32(3):279-83. Review.

PMID:
15988682
15.

Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival.

Ichinose Y, Hara N, Ohta M, Motohiro A, Kuda T, Aso H.

J Surg Oncol. 1991 Jan;46(1):15-20.

PMID:
1702493
16.

Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.

Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC.

J Cell Biochem Suppl. 1996;24:173-85.

PMID:
8806100
17.
18.

Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.

d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ.

Ann Thorac Surg. 2006 Feb;81(2):440-6; discussion 446-7.

PMID:
16427828
19.

Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.

Johnson BE, Rabin MS.

Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s. Review.

20.

Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.

Wakelee H, Dubey S, Gandara D.

Oncologist. 2007 Mar;12(3):331-7. Review.

Supplemental Content

Support Center